"Novel Psychopharmacology for Depressive Disorders"
Michele Fornaro1,2, Domenico De Berardis3,4, Annalisa Anastasia3
1Department of Psychiatry, Federico II University of Naples, Naples, Italy. dott.fornaro@gmail.com.
Abstract:
Major depressive disorder carries a significant burden and a high risk for suicide. The need for more effective, safer, and faster-acting drugs is, therefore, compelling. The present chapter briefly assesses the most promising agents, focusing on non-monoamine-targeting compounds, namely, the glutamate antagonist ketamine and its enantiomer esketamine. A critical overview of the evidence and the pitfalls associated with current antidepressant drug development is likewise provided in the following text.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Depressive Disorders: MDD and Dysthymia
Depression: Overview


